Literature DB >> 10221518

Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines.

K G Steube1, C Meyer, S Habig, C C Uphoff, H G Drexler.   

Abstract

HTK (hepatoma transmembrane kinase) is a receptor tyrosine kinase belonging to the EPH subfamily of tyrosine kinases. Binding of its ligand (HTKL) results in tyrosine phosphorylation of HTK. In the present study, we analyzed the possible involvement of this ligand-receptor signalling system in hematopoiesis by examining the expression of both HTK and HTKL in a large and comprehensive panel of 70 continuous human leukemia-lymphoma cell lines. HTK and HTKL mRNA expression were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). HTK mRNA was detected in 68/70 cell lines; 58/70 cell lines were positive for HTKL mRNA expression; consequently, co-expression of both receptor and ligand was demonstrated in the majority of cell lines. Collectively, the wide-spread expression suggests a role for this ligand-receptor pair in hematopoietic development and/or function. Investigation of the details of signal transduction pathway that is activated by the HTK tyrosine kinase will help to define the exact biological function of the HTK-HTKL system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221518     DOI: 10.3109/10428199909058438

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Authors:  Benjamin D Ferguson; Maria S Tretiakova; Mark W Lingen; Parkash S Gill; Ravi Salgia
Journal:  Growth Factors       Date:  2014-11-13       Impact factor: 2.511

2.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Authors:  S Charmsaz; F Al-Ejeh; T M Yeadon; K J Miller; F M Smith; B W Stringer; A S Moore; F-T Lee; L T Cooper; C Stylianou; G T Yarranton; J Woronicz; A M Scott; M Lackmann; A W Boyd
Journal:  Leukemia       Date:  2016-12-06       Impact factor: 11.528

4.  EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Authors:  Akil A Merchant; Aparna Jorapur; Amy McManus; Ren Liu; Valery Krasnoperov; Parvesh Chaudhry; Mohan Singh; Lisa Harton; Mary Agajanian; Miriam Kim; Timothy J Triche; Brian J Druker; Jeffrey W Tyner; Parkash S Gill
Journal:  Blood Adv       Date:  2017-08-28

5.  Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.

Authors:  Min-A Seol; In-Sun Chu; Mi-Jin Lee; Goung-Ran Yu; Xiang-Dan Cui; Baik-Hwan Cho; Eun-Kyung Ahn; Sun-Hee Leem; In-Hee Kim; Dae-Ghon Kim
Journal:  BMC Cancer       Date:  2011-02-19       Impact factor: 4.430

6.  EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

Authors:  Sara Charmsaz; Kirrilee Beckett; Fiona M Smith; Claudia Bruedigam; Andrew S Moore; Fares Al-Ejeh; Steven W Lane; Andrew W Boyd
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

Review 7.  Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.

Authors:  Kalpana K Bhanumathy; Amrutha Balagopal; Frederick S Vizeacoumar; Franco J Vizeacoumar; Andrew Freywald; Vincenzo Giambra
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.